A multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os (ARCANGELO)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/43794
• EU PAS number:
  EUPAS36393
• Study ID:
  43794
• Official title and acronym:
  A multicentre observational, prospective cohort study including patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. transitioning to either clopidogrel, prasugrel or ticagrelor per os (ARCANGELO)
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study status:
  Finalised

Research institutions and networks

Institutions

San Camillo Forlanini

Study timelines

Date when funding contract was signed

Planned: 31/07/2020

Actual: 06/08/2020

Study start date

Planned: 31/10/2020

Actual: 23/10/2020

Date of interim report, if expected

Planned: 30/04/2021

Actual: 20/04/2021

Date of final study report

Planned: 31/01/2023

Actual: 20/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Chiesi Farmaceutici

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)